VINP vs OMER Comparison

Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.